Monoethanolamine
CAS 141-43-5
Monoethanolamine (CAS 141-43-5) is a Phase 2 pharmaceutical compound with 3 bioactivity targets and 2 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | Potency | 34718.76666666666 nM | 6 | - |
| - | AC50 | 4630.533333333334 nM | 3 | - |
| - | IC50 | 19976.309999999998 nM | 1 | - |
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| 2-AMINOETHANOL | 24457 | SU | MTHSPL |
| MONOETHANOLAMINE | 24457 | SU | MTHSPL |
| monoethanolamine | 24457 | SY | RXNORM |
| ethanolamine | 24457 | IN | RXNORM |
Side Effects
SIDER side-effect terms mapped to the drug or same-CAS compound identity.
| Side Effect | Drug Name | MedDRA Type | Concept ID |
|---|---|---|---|
| Abscess | monoethanolamine | LLT | C0000833 |
| Abscess | monoethanolamine | PT | C0000833 |
| Anaphylactic shock | monoethanolamine | LLT | C0002792 |
| Anaphylactic shock | monoethanolamine | PT | C0002792 |
| Bacteraemia | monoethanolamine | LLT | C0004610 |
| Bacteraemia | monoethanolamine | PT | C0004610 |
| Body temperature increased | monoethanolamine | LLT | C0015967 |
| Body temperature increased | monoethanolamine | PT | C0015967 |
| Chest pain | monoethanolamine | PT | C0008031 |
| Disseminated intravascular coagulation | monoethanolamine | LLT | C0012739 |
| Disseminated intravascular coagulation | monoethanolamine | PT | C0012739 |
| Lacrimation | monoethanolamine | LLT | C0423153 |
| Lacrimation increased | monoethanolamine | PT | C0152227 |
| Necrosis | monoethanolamine | LLT | C0027540 |
| Necrosis | monoethanolamine | PT | C0027540 |
| Oesophageal stenosis | monoethanolamine | LLT | C0014866 |
| Oesophageal stenosis | monoethanolamine | PT | C0014866 |
| Oesophageal ulcer | monoethanolamine | LLT | C0151970 |
| Oesophageal ulcer | monoethanolamine | PT | C0151970 |
| Oesophagitis | monoethanolamine | LLT | C0014868 |
| Oesophagitis | monoethanolamine | PT | C0014868 |
| Pain | monoethanolamine | LLT | C0030193 |
| Pain | monoethanolamine | PT | C0030193 |
| Pleural effusion | monoethanolamine | LLT | C0032227 |
| Pleural effusion | monoethanolamine | PT | C0032227 |
| Pneumonia | monoethanolamine | LLT | C0032285 |
| Pneumonia | monoethanolamine | PT | C0032285 |
| Pneumonia aspiration | monoethanolamine | LLT | C0032290 |
| Pneumonia aspiration | monoethanolamine | PT | C0032290 |
| Renal failure acute | monoethanolamine | LLT | C0022660 |
| Renal failure acute | monoethanolamine | PT | C0022660 |
| Retrosternal pain | monoethanolamine | LLT | C0151826 |
| Spinal cord paralysis | monoethanolamine | LLT | C1112349 |
| Spinal cord paralysis | monoethanolamine | PT | C1112349 |
| Ulcer | monoethanolamine | LLT | C0041582 |
| Ulcer | monoethanolamine | PT | C0041582 |
| Varicose vein | monoethanolamine | LLT | C0042345 |
| Varicose vein | monoethanolamine | PT | C0042345 |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Monoethanolamine used for in pharmaceutical contexts?
Monoethanolamine (CAS 141-43-5) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Monoethanolamine?
Monoethanolamine has 2 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Fatigue, Insomnia. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Monoethanolamine also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Monoethanolamine (MEA) with EU status "restricted".
What clinical phase is Monoethanolamine in?
Monoethanolamine is rendered with ChEMBL max phase 2.